Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment

Susan B. Bressler, Allison R. Ayala, Neil M. Bressler, Michele Melia, Haijing Qin, Frederick L. Ferris, Christina Flaxel, Scott M. Friedman, Adam R. Glassman, Lee M. Jampol, Michael E. Rauser

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

IMPORTANCE: The prevalence of persistent diabetic macular edema (DME) after months of anti-vascular endothelial growth factor therapy and its effect on visual acuity are unknown. OBJECTIVE: To assess subsequent outcomes of eyes with DME persisting for 24 weeks after initiating treatment with 0.5 mg of ranibizumab. DESIGN, SETTING, AND PARTICIPANTS: We performed post hoc, exploratory analyses of a randomized clinical trial from March 20, 2007, through January 29, 2014, from 117 of 296 eyes (39.5%) randomly assigned to receive ranibizumab with persistent DME (central subfield thickness ≥250 μm on time domain optical coherence tomography) through the 24-week visit. INTERVENTIONS: Four monthly intravitreous injections of ranibizumab and then as needed per protocol. MAIN OUTCOMES AND MEASURES: Cumulative 3-year probabilities of chronic persistent DME (failure to achieve a central subfield thickness

Original languageEnglish (US)
Pages (from-to)278-285
Number of pages8
JournalJAMA Ophthalmology
Volume134
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Macular Edema
Optical Coherence Tomography
Therapeutics
Vascular Endothelial Growth Factor A
Visual Acuity
Randomized Controlled Trials
Injections
Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Bressler, S. B., Ayala, A. R., Bressler, N. M., Melia, M., Qin, H., Ferris, F. L., ... Rauser, M. E. (2016). Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmology, 134(3), 278-285. https://doi.org/10.1001/jamaophthalmol.2015.5346

Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. / Bressler, Susan B.; Ayala, Allison R.; Bressler, Neil M.; Melia, Michele; Qin, Haijing; Ferris, Frederick L.; Flaxel, Christina; Friedman, Scott M.; Glassman, Adam R.; Jampol, Lee M.; Rauser, Michael E.

In: JAMA Ophthalmology, Vol. 134, No. 3, 01.03.2016, p. 278-285.

Research output: Contribution to journalArticle

Bressler, SB, Ayala, AR, Bressler, NM, Melia, M, Qin, H, Ferris, FL, Flaxel, C, Friedman, SM, Glassman, AR, Jampol, LM & Rauser, ME 2016, 'Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment', JAMA Ophthalmology, vol. 134, no. 3, pp. 278-285. https://doi.org/10.1001/jamaophthalmol.2015.5346
Bressler, Susan B. ; Ayala, Allison R. ; Bressler, Neil M. ; Melia, Michele ; Qin, Haijing ; Ferris, Frederick L. ; Flaxel, Christina ; Friedman, Scott M. ; Glassman, Adam R. ; Jampol, Lee M. ; Rauser, Michael E. / Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. In: JAMA Ophthalmology. 2016 ; Vol. 134, No. 3. pp. 278-285.
@article{cee354e04e53471891997f199cd49b6d,
title = "Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment",
abstract = "IMPORTANCE: The prevalence of persistent diabetic macular edema (DME) after months of anti-vascular endothelial growth factor therapy and its effect on visual acuity are unknown. OBJECTIVE: To assess subsequent outcomes of eyes with DME persisting for 24 weeks after initiating treatment with 0.5 mg of ranibizumab. DESIGN, SETTING, AND PARTICIPANTS: We performed post hoc, exploratory analyses of a randomized clinical trial from March 20, 2007, through January 29, 2014, from 117 of 296 eyes (39.5{\%}) randomly assigned to receive ranibizumab with persistent DME (central subfield thickness ≥250 μm on time domain optical coherence tomography) through the 24-week visit. INTERVENTIONS: Four monthly intravitreous injections of ranibizumab and then as needed per protocol. MAIN OUTCOMES AND MEASURES: Cumulative 3-year probabilities of chronic persistent DME (failure to achieve a central subfield thickness",
author = "Bressler, {Susan B.} and Ayala, {Allison R.} and Bressler, {Neil M.} and Michele Melia and Haijing Qin and Ferris, {Frederick L.} and Christina Flaxel and Friedman, {Scott M.} and Glassman, {Adam R.} and Jampol, {Lee M.} and Rauser, {Michael E.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1001/jamaophthalmol.2015.5346",
language = "English (US)",
volume = "134",
pages = "278--285",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment

AU - Bressler, Susan B.

AU - Ayala, Allison R.

AU - Bressler, Neil M.

AU - Melia, Michele

AU - Qin, Haijing

AU - Ferris, Frederick L.

AU - Flaxel, Christina

AU - Friedman, Scott M.

AU - Glassman, Adam R.

AU - Jampol, Lee M.

AU - Rauser, Michael E.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - IMPORTANCE: The prevalence of persistent diabetic macular edema (DME) after months of anti-vascular endothelial growth factor therapy and its effect on visual acuity are unknown. OBJECTIVE: To assess subsequent outcomes of eyes with DME persisting for 24 weeks after initiating treatment with 0.5 mg of ranibizumab. DESIGN, SETTING, AND PARTICIPANTS: We performed post hoc, exploratory analyses of a randomized clinical trial from March 20, 2007, through January 29, 2014, from 117 of 296 eyes (39.5%) randomly assigned to receive ranibizumab with persistent DME (central subfield thickness ≥250 μm on time domain optical coherence tomography) through the 24-week visit. INTERVENTIONS: Four monthly intravitreous injections of ranibizumab and then as needed per protocol. MAIN OUTCOMES AND MEASURES: Cumulative 3-year probabilities of chronic persistent DME (failure to achieve a central subfield thickness

AB - IMPORTANCE: The prevalence of persistent diabetic macular edema (DME) after months of anti-vascular endothelial growth factor therapy and its effect on visual acuity are unknown. OBJECTIVE: To assess subsequent outcomes of eyes with DME persisting for 24 weeks after initiating treatment with 0.5 mg of ranibizumab. DESIGN, SETTING, AND PARTICIPANTS: We performed post hoc, exploratory analyses of a randomized clinical trial from March 20, 2007, through January 29, 2014, from 117 of 296 eyes (39.5%) randomly assigned to receive ranibizumab with persistent DME (central subfield thickness ≥250 μm on time domain optical coherence tomography) through the 24-week visit. INTERVENTIONS: Four monthly intravitreous injections of ranibizumab and then as needed per protocol. MAIN OUTCOMES AND MEASURES: Cumulative 3-year probabilities of chronic persistent DME (failure to achieve a central subfield thickness

UR - http://www.scopus.com/inward/record.url?scp=84962377210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962377210&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2015.5346

DO - 10.1001/jamaophthalmol.2015.5346

M3 - Article

C2 - 26746868

AN - SCOPUS:84962377210

VL - 134

SP - 278

EP - 285

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 3

ER -